Sebastian Biopharma is a preclinical oncology company developing tumor-targeted, multi-pathway therapeutics to address immunotherapy-resistant cancers where most patients with solid tumors fail to ach ...

InterAct Therapeutics (IAT) is a preclinical biotechnology company developing genetic medicines for metastatic cancer. Its core platform is designed specifically to address metastasis by identifying a ...

JJDC is the venture capital subsidiary of Johnson & Johnson. JJDC invests in biotech and medtech private companies that are on-strategy for J&J.

Ymmunobio achieves 100% tumor eradication with their lead ADC YB-811 after only four doses (10 mg/kg) with no off-target toxicity! What If You Could Give Cancer Patients Years They Never Expected?Imag ...

3i Fund is a newly formed umbrella company of the single family office White Bay Group.

Abiozen is a regulatory-driven, AI-enabled life-science platform supporting early-stage and virtual biotech companies from research molecule sourcing through quality control and early clinical develop ...

Advantary and our capital partners are sector- and stage-agnostic investors using an SPV model that focuses on you and your company. We invest in revenue-generating companies at the pre-seed, seed, an ...

Aetherium Bio is developing multi-targeting therapeutics for chronic inflammatory diseases driven by chemokine-mediated immune cell infiltration into tissues. Our proprietary computational platform un ...

Alphabet Ventures, an Alphabet Health Group company, is a global biopharma and medtech investment company that aim to accelerate innovations. Our investment thesis focuses on science, unmet need, comm ...